

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 August 2005 (18.08.2005)

PCT

(10) International Publication Number
WO 2005/074995 A2

- (51) International Patent Classification⁷: **A61K 48/00**
- (74) Agents: BRASNETT, Adrian et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London Greater London WC2B 6HP (GB).
- (21) International Application Number:
PCT/EP2005/000937
- (22) International Filing Date: 27 January 2005 (27.01.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0401876.8 28 January 2004 (28.01.2004) GB
- (71) Applicant (for all designated States except US): VERENIGING HET NEDERLANDS KANKER INSTITUUT [NL/NL]; Plesmanlaan 121, NL-1066 CX Amsterdam (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BERNARDS, René [NL/NL]; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, NL-1066 CX Amsterdam (NL). EPPING, Mirjam [NL/NL]; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, NL-1066 CX Amsterdam (NL). WANG, Liming [CN/NL]; The Netherlands Cancer Institute, Plesmanlaan 121, NL-1066 CX Amsterdam (NL).
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINED USE OF PRAME INHIBITORS AND HDAC INHIBITORS

(57) Abstract: The invention relates to the cancer antigen PRAME (PReferentially expressed Antigen in MELanoma) and its use in a method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid.

WO 2005/074995 A2